Research programme: thapsigargin analogues - Inspyr Therapeutics

Drug Profile

Research programme: thapsigargin analogues - Inspyr Therapeutics

Alternative Names: Ac-GKAFRR-L12ADT; G-114; G-115; G-301; Plant-derived cytotoxin- Inspyr Therapeutics; Thapsigargin analogues research programme- Inspyr Therapeutics

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GenSpera
  • Developer Inspyr Therapeutics
  • Class Lactones; Peptides; Sesquiterpenes
  • Mechanism of Action Sarcoplasmic reticulum calcium-transporting ATPase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Prostate cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Prostate-cancer in USA (IV)
  • 01 Aug 2016 GenSpera is now called Inspyr Therapeutics
  • 06 May 2015 GenSpera has patents pending for injectable cancer compositions of thapsigargin-containing prodrugs in 17 countries, including Europe, Eurasia, Japan, China, Brazil and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top